UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of November 2026
Commission
File Number: 001-42915
Alps
Group Inc
(Registrant’s
Name)
Unit
E-18-01 & E-18-02, Level 18, Icon Tower (East)
No.
1, Jalan 1/68F, Jalan Tun Razak
50400
Kuala Lumpur
Wilayah
Persekutuan, Malaysia
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information
Contained in this Form 6-K Report
Attached
hereto as Exhibit 99.1 is a press release dated November 20, 2026 issued by Alps Group Inc (the “Company”) announcing that
it has received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC confirming that the Company
has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market.
Exhibits
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press Release dated November 20, 2026 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Alps
Group Inc |
| |
|
|
| Date:
November 20, 2026 |
By: |
/s/
Dr. Seng Kong Tham |
| |
Name:
|
Dr.
Seng Kong Tham |
| |
Title: |
Chief
Executive Officer and Director |
Exhibit 99.1

Alps
Group Inc Regains Compliance with Nasdaq Minimum Bid Price Requirement
KUALA
LUMPUR, Malaysia – November 20, 2026 – Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS),
an integrated biotechnology platform headquartered in Malaysia, today announced that it has received written notification from the Listing
Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with
the minimum bid price requirement for continued listing on The Nasdaq Global Market.
On
May 19, 2026, the Company previously disclosed that, on May 15, 2026, the Company received a letter from Nasdaq notifying the Company
that based on the closing bid price of the ordinary shares of the Company for the prior 30 consecutive business days, the Company was
not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company
to maintain a minimum bid price of $1.00 per share.
On
November 9, 2026, the Company’s ordinary shares began trading on a post-consolidation basis following the Company’s previously
announced 1-for-5 share consolidation.
On
November 16, 2026, the Company received a letter from the Nasdaq Listing Qualifications Staff stating that the Company had not regained
compliance with Nasdaq Listing Rule 5450(a)(1), which required the listed ordinary shares to maintain a closing bid price of $1.00 per
share for 10 consecutive business days, by November 11, 2026, the end of the applicable compliance period, and that the Staff had determined
that the Company’s ordinary shares would be subject to delisting.
On
November 20, 2026, the Nasdaq Listing Qualifications Staff notified the Company that the closing bid price of its ordinary shares had
been $1.00 per share or greater for 10 consecutive business days, from November 9, 2026 to November 20, 2026. Accordingly, the Company
has regained compliance with the minimum bid price requirement, and Nasdaq has confirmed that the matter is now closed.
The
notification has no effect on the trading of the Company’s ordinary shares which continue to trade on The Nasdaq Global Market
under the symbol “ALPS.”
About
Alps Group Inc
Alps
Group Inc is a revenue-generating integrated biotechnology platform headquartered in Malaysia, operating across cell manufacturing, molecular
diagnostics, and clinical delivery. Alps leverages revenue from its commercial businesses to support its clinical pipeline development,
with a mission to make advanced precision medicine accessible and affordable across Southeast Asia.

Forward-Looking
Statements
Certain
statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of
“safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified
by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,”
“anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,”
“intend,” “plan,” “project” and other similar expressions that predict or indicate future events
or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of
future performance. Instead, they are based only on the Company’s management’s current beliefs, expectations, and assumptions.
Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances
that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those
indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
A
further list and description of risks and uncertainties can be found in documents filed with or furnished to the Securities and Exchange
Commission (“SEC”) by the Company and other documents that we may file with or furnish to the SEC, which you are encouraged
to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company
and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise,
except as required by law.
Investor
Relations Contact
Alps Group Inc
Investor Relations
Phone: +60 3-2163 1113
Email: investorrelations@alpsmedical.com